Key Developments: ARIAD Pharmaceuticals Inc (ARIA.O)

ARIA.O on Nasdaq

27 Nov 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

ARIAD Pharmaceuticals Inc announces long-term safety and efficacy data of ponatinib from phase 2 pace clinical trail
Friday, 12 Jun 2015 11:15am EDT 

ARIAD Pharmaceuticals Inc:Says responses have been maintained long-term in cp-cml patients.Says median follow-up now approximately 3.5 years for chronic phase cml patients.Additionally, 95 percent of cp-cml patients who underwent ponatinib dose reductions maintained their responses.  Full Article

Ariad and Paladin announce commercial distribution agreement for iclusig in Canada
Wednesday, 10 Jun 2015 07:35am EDT 

Ariad Pharmaceuticals Inc and Paladin Labs Inc:Says commercial distribution agreement for Iclusig (ponatinib) in Canada.Says Ariad will continue to be the marketing authorization holder of Iclusig in Canada.Paladin will be responsible for distribution, sales and marketing, medical affairs, and pricing and reimbursement activities.Says Paladin will book sales of Iclusig in Canada while Ariad will supply packaged drug to Paladin.Granted Paladin, an operating co of Endo International, rights to distribute Iclusig in Canada for its newly approved indications.  Full Article

Harvey J. Berger to retire as Chairman and CEO of ARIAD Pharmaceuticals
Wednesday, 29 Apr 2015 06:49am EDT 

ARIAD Pharmaceuticals Inc:Says Harvey J. Berger to retire as Chairman and Chief Executive Officer (CEO) upon the appointment of his successor or Dec. 31, whichever is earlier.  Full Article

Ariad announces issuance of key U.S. patent on Brigatinib
Wednesday, 22 Apr 2015 07:35am EDT 

Ariad Pharmaceuticals Inc:Announces the issuance of its first U.S. patent on brigatinib, ARIAD's investigational ALK inhibitor.The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, Phosphorous Derivatives as Kinase Inhibitors.The patent provides composition-of-matter protection through at least Dec. 30, 2030 for ARIAD's investigational ALK inhibitor, brigatinib.Additional patent applications covering brigatinib are pending in the U.S. and in other countries.  Full Article

Ariad Pharmaceuticals announces results of preclinical studies on Brigatinib at the American Association for Cancer Research Annual Meeting
Tuesday, 21 Apr 2015 07:35am EDT 

Ariad Pharmaceuticals Inc:Says results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at the American Association for Cancer Research (AACR) Annual Meeting 2015.Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC), who are resistant to crizotinib.  Full Article

ARIAD Pharmaceuticals Inc announces dismissal of shareholder class action lawsuit in Federal District Court
Wednesday, 25 Mar 2015 09:28am EDT 

ARIAD Pharmaceuticals Inc:Says U.S. District Court for district of massachusetts dismissed shareholder class action lawsuit filed in late 2013 against company and certain of officers, directors.Says underwriters in this connection with events leading up to temporary suspension of marketing and commercial distribution of Iclusig on Oct. 31, 2013, and subsequent re-launch in Jan. 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy.Says suit alleged that certain of company defendants made a series of false and misleading statements regarding the safety, efficacy and commercial prospects of Iclusig.  Full Article

Ariad and STA announces approval of Iclusig (Ponatinib) in Australia
Monday, 24 Nov 2014 07:35am EST 

Ariad Pharmaceuticals Inc and Specialised Therapeutics Australia Pty Ltd:Receives marketing approval of Iclusig (ponatinib) in Australia by the Therapeutic Goods Administration (TGA).Commercial launch of Iclusig is expected to occur early in 2015.  Full Article

Ariad Pharmaceuticals Inc announces recommendation for Iclusig by Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
Friday, 10 Oct 2014 07:44am EDT 

Ariad Pharmaceuticals Inc:Says Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig (ponatinib) under the Article 20 referral procedure.Recommends that Iclusig continue to be used in Europe in accordance with its already approved indications.  Full Article

Ariad and Bellicum announces revised license agreement for ARIAD's Cell-Signaling Technology
Monday, 6 Oct 2014 07:35am EDT 

Ariad Pharmaceuticals Inc:Says Bellicum Pharmaceuticals, Inc. and Ariad Pharmaceuticals, Inc. announces restructuring of their license agreement for Ariad's cell-signaling technology.Ariad will receive $50 mln in exchange for fully paid up license to this technology and return of its equity stake in closely held Bellicum.The scope of license and field of use were also expanded as part of amendment.Under terms of revised agreement, Ariad will receive $50 mln in three installments: $15 mln upon signing of the agreement, $20 mln by June 30, 2015, and $15 mln by June 30, 2016.The last payment may be accelerated to the fourth quarter of 2015 under certain circumstances.Says restructured agreement gives Bellicum worldwide exclusive license to Ariad's cell-signaling technology for broad use in human cell therapies for all diseases on royalty- and milestone-free basis.  Full Article

Ariad Pharmaceuticals's AP26113 receives FDA breakthrough therapy designation
Thursday, 2 Oct 2014 07:55am EDT 

ARIAD Pharmaceuticals Inc:Says that it has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib.Says this designation is based on results from the ongoing Phase 1/2 trial that show sustained anti-tumor activity of AP26113 in patients with ALK+ NSCLC, including patients with active brain metastases.  Full Article

Drugmaker Baxalta in talks to buy Ariad: Bloomberg

Drugmaker Baxalta Inc is in talks to buy Ariad Pharmaceuticals Inc to boost its oncology business, Bloomberg reported, citing people familiar with the matter.

Search Stocks